OLDSMAR, Fla., Aug. 6 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL), one of the largest and most established leaders in stem cell innovation, will present data on the proliferative ability of stem cells found in menstrual blood (known as MenSCs) during the Fourth China Medical Biotech Forum, August 8-10 in Dalian, China. Data from an in vitro study show that MenSCs proliferate rapidly and have significant potential to develop into multiple cell types. Dr. Julie Allickson, Vice President of Laboratory Operations and Research and Development at Cryo-Cell, will present the data at the Forum as part of a keynote address.
The data being presented are based on research conducted by Cryo-Cell International, who discovered the menstrual stem cells. The data show that MenSCs have the capability to differentiate rapidly and plentifully into stem cells, such as bone, cartilage, fat, nerve and cardiogenic cells. These findings demonstrate that menstrual stem cells are easily expandable to clinical relevance and may potentially have applications in a variety of conditions. Using Cryo-Cell's proprietary C'elle(SM) system, MenSCs are currently being studied for potential therapeutic applications for possible future treatment of disorders such as stroke; diabetes; vascular regeneration; breast cancer; wound management; endometriosis and female urinary incontinence.
"We are pleased to share these promising early study findings with the distinguished researchers attending the CMBF," said Dr. Allickson. "MenSCs are sufficiently potent and could potentially be used in the future for a variety of therapies and conditions, and we look forward to gaining further insights from the current clinical trials testing the safety and efficacy of the cells in several different animal models."
The C'elle service is based on Cryo-Cell's expansive IP technology portfolio and was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly first-degree relatives in a manner similar to umbilical cord blood stem cells. Based on the continuing success of MenSCs in the research setting, Cryo-Cell is actively expanding its portfolio of research collaborations with world renowned scientists committed to study this novel stem cell population for a broad range of regenerative therapeutic development.
"Cryo-Cell's keynote presentation at the China Medical Biotech Forum is a strategic opportunity that comes at an exciting time for global stem cell research and development," stated Mercedes A. Walton, Cryo-Cell's Chairman & CEO. "The Company continues to build a robust intellectual property portfolio based on Cryo-Cell's menstrual stem cell technology. We are honored to share the Company's research with preeminent scientists and physicians who are attending the China Medical Biotech Forum from around the world."
About the China Medical Biotech Forum
The Forum invites officers from related government departments of China to give special reports on key issues and relevant policies regarding the development of medicinal biotechnology. It also provides renowned scientists the opportunity to make presentations on their latest progress. Presentations focus on topics such as vaccine separation, purification and application; antibody and peptide drug research and clinical application; the latest developments of enzyme engineering and fermentation engineering; as well as regenerative medicine technology research and its standard, nanobiotechnology research.
The C'elle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.celle.com.
About Cryo-Cell International, Inc. (OTCBB: CCEL.OB)
Based in Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.
Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to types of stem cells other than cord blood stem cells, including the C'elle service, given that menstrual stem cells and other new stem cells have not yet been used in human therapies, and treatment applications using such stem cells may not be developed and commercialized; or if they are not likely to be developed or commercialized for many years and are subject to further research and development; the need for additional development and testing before determining the ultimate commercial value of the Company's intellectual property relating to the menstrual stem cells; the need to complete certain developments, including completion of clinical validation and testing, before any new process other than C'elle can be commercialized, and the Company's development of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store stem cells or decrease in the number of people paying annual storage fees; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; and any other risk factors described in our filing with the Securities and Exchange Commission. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should also carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.
Contact: General Media Inquiries Kristin Boza 312-233-1295 email@example.com Financial Media Inquiries: Cryo-Cell International, Inc. Investor Relations Dianne Will 518-398-6222 firstname.lastname@example.org
|SOURCE Cryo-Cell International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved